ESPE Abstracts (2018) 89 P-P2-313

Neuroendocrine Consequences of Hypothalamic Hamartoma and their Imaging (MRI) and Surgery Correlates

Beatriz Corredora, Elisabetta Careddaa, Ash Ederiesb, Martin Tisdallc, Helen Crossd & Helen A. Spoudeasa


aEndocrinology, Great Ormond Street Hospital for Children, London, UK; bNeuroimaging, Great Ormond Street Hospital for Children, London, UK; cNeurosurgery, Great Ormond Street Hospital for Children, London, UK; dNeurology, Great Ormond Street Hospital for Children, London, UK


Background: Hypothalamic hamartomas(HH) are rare heterotopic congenital malformations causing central precocious puberty(CPP) and/or resistant epilepsy whose natural history is unknown.

Aim: To describe clinical and imaging features, and the risk of developing endocrine deficits, particularly after surgery.

Method: Retrospective case note and imaging review of all HH diagnosed by MRI between 30.08.1991 and 24.11.17, analysed by initial presentation, imaging (Delalande grading), and surgery.

Results: 59 (36male) children of median age 2.72 (antenatal-15.59) years at diagnosis presented with A) gelastic/dacrystic epilepsy (n32) at 5.62 (0.16-15.59) years, B) CPP(n17) at 1.35 (0.64-8.49) years or C) incidentally (n10) at 0.9 (antenatal-9.78) years of whom one was diagnosed with CPP 0.41 years later. 14 (9=GpA,5=GpB) respectively developed additional CPP after 1.83 (0.19-5.83) or epilepsy after 0.55 (0.17-1.0) years. Despite 60% experiencing seizures in their first year, 37 with epilepsy, had a 2.96 years delay in HH diagnosis compared with 27 with CPP (Mann-Whitney P<0.05). Grade 1 tumours (below 3rd ventricle) were more often associated with CPP than Grade 2 or 3 tumours (above 3rd ventricle), more likely to cause epilepsy (x2P<0.05). 66% (n=39/59) were followed endocrinologically for 5.32 (0.29-14.34) years. At last assessment, BMI and height SDS were 0.54 (-3.68_3.63) and 0.19 (-1_1.80) respectively; in 66%(n=26/39) BMI increased by 1.05 (0.1-4.18) SDS. GH deficiency (GHD) occurred in just 2 (unoperated). 20(18=GpA,2=GpB) underwent surgery (4=endoscopic, 10=open, 4=radiosurgery, 2=laser) for intractable epilepsy at 8.10 (0.17-16.88) years, 3 of whom required multiple attempts [(endoscopic+laser) (4endoscopic+open+radiosurgery), (open+radiosurgery+open)]. In 14/20 followed after surgery, 4 (29%) developed TSHD after 0.61 (0.18-1.51)years, 3 (21%) GHD at 1.89 (1.40-3.45)years of whom 2 also had ACTHD and CDI [one after 3 endoscopic surgeries and another with additional TSHD, LH/FSHD after laser surgery and earlier CPP, and GHD from earlier endoscopic resection]. One patient developed isolated CDI and two hypodipsia after open surgery. GHD and ACTHD were associated with endoscopic surgery, P<0.05.

Conclusion: Grade 1 HH more often cause CPP, and grade 2/3 tumours epilepsy, but the features overlap and all should be endocrinologically screened for CPP, GHD and obesity over time. Surgery causes additional deficits in 50% of those operated, with life-threatening CDI and ACTHD in 15%, including one who received modern laser surgery. These data help inform therapeutic choices and hypothalamic morbidity in this disease and require close monitoring.

Article tools

My recent searches

No recent searches.